» Articles » PMID: 28541132

How Can We Realize the Clinical Benefits of Continuous Glucose Monitoring?

Overview
Date 2017 May 26
PMID 28541132
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Controlling glycemia in diabetes remains key to prevent complications in this condition. However, glucose levels can undergo large fluctuations secondary to daily activities, consequently creating management difficulties. The current review summarizes the basics of glucose management in diabetes by addressing the main glycemic parameters. The advantages and limitation of HbA1c, the gold standard measure of glucose control, are discussed together with the clinical importance of hypoglycemia and glycemic variability. The review subsequently moves focus to glucose monitoring techniques in diabetes, assessing advantages and limitations. Monitoring glucose levels is crucial for effective and safe adjustment of hypoglycemic therapy, particularly in insulin users. Self-monitoring of blood glucose (SMBG), based on capillary glucose testing, remains one of the most widely used methods to monitor glucose levels, given the relative accuracy, familiarity, and manageable costs. However, patient inconvenience and the sporadic nature of SMBG limit clinical effectiveness of this approach. In contrast, continuous glucose monitoring (CGM) provides a more comprehensive picture of glucose levels, but these systems are expensive and require constant calibration which, together with concerns over accuracy of earlier devices, restrict CGM use to special groups of patients. The newer flash continuous glucose monitoring (FCGM) system, which is more affordable than conventional CGM devices and does not require calibration, offers an alternative glucose monitoring strategy that comprehensively analyzes glucose profile while sparing patients the inconvenience of capillary glucose testing for therapy adjustment or CGM calibration. The fast development of new CGM devices will gradually displace SMBG as the main glucose testing method. Avoiding the inconvenience of SMBG and optimizing glycemia through alternative glucose testing strategies will help to reduce the risk of complications and improve quality of life in patients with diabetes.

Citing Articles

Impact of Continuous Glucose Monitoring on Hemoglobin A1c and Height Trends in Latin American Children with Type 1 Diabetes Onset over 3 Years: A Multicenter Study.

Hirschler V, Molinari C, Gonzalez C J Pediatr Clin Pract. 2024; 14:200130.

PMID: 39639861 PMC: 11617742. DOI: 10.1016/j.jpedcp.2024.200130.


The clinical importance of measuring glycaemic variability: Utilising new metrics to optimise glycaemic control.

Ajjan R Diabetes Obes Metab. 2024; 26 Suppl 7:3-16.

PMID: 39632776 PMC: 11646482. DOI: 10.1111/dom.16098.


The benefits and accuracy of real-time continuous glucose monitoring in children and adolescents with type 1 diabetes attending a summer camp.

Kondo T, Senokuchi T, Morinaga J, Miyashita A, Yano M, Takeda H J Diabetes Investig. 2024; 16(1):154-162.

PMID: 39474860 PMC: 11693605. DOI: 10.1111/jdi.14337.


Perspective of Continuous Glucose Monitoring-Based Interventions at the Various Stages of Type 2 Diabetes.

Ajjan R, Seidu S, Riveline J Diabetes Ther. 2024; 15(8):1657-1672.

PMID: 38907936 PMC: 11263446. DOI: 10.1007/s13300-024-01607-5.


Expert Opinion on Current Trends in the Use of Insulin in the Management of People with Type 2 Diabetes from the South-Eastern European Region and Israel.

Tabak A, Kempler P, Guja C, Eldor R, Haluzik M, Klupa T Diabetes Ther. 2024; 15(5):897-915.

PMID: 38472626 PMC: 11043254. DOI: 10.1007/s13300-024-01556-z.


References
1.
Matuleviciene V, Joseph J, Andelin M, Hirsch I, Attvall S, Pivodic A . A clinical trial of the accuracy and treatment experience of the Dexcom G4 sensor (Dexcom G4 system) and Enlite sensor (guardian REAL-time system) tested simultaneously in ambulatory patients with type 1 diabetes. Diabetes Technol Ther. 2014; 16(11):759-67. PMC: 4201312. DOI: 10.1089/dia.2014.0238. View

2.
Khunti K, Davies M, Majeed A, Thorsted B, Wolden M, Paul S . Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care. 2014; 38(2):316-22. DOI: 10.2337/dc14-0920. View

3.
Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y . Effect of daily glucose fluctuation on coronary plaque vulnerability in patients pre-treated with lipid-lowering therapy: a prospective observational study. JACC Cardiovasc Interv. 2015; 8(6):800-811. DOI: 10.1016/j.jcin.2014.11.025. View

4.
Suh S, Kim J . Glycemic Variability: How Do We Measure It and Why Is It Important?. Diabetes Metab J. 2015; 39(4):273-82. PMC: 4543190. DOI: 10.4093/dmj.2015.39.4.273. View

5.
Goto A, Arah O, Goto M, Terauchi Y, Noda M . Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ. 2013; 347:f4533. DOI: 10.1136/bmj.f4533. View